Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Report Lantus Biosimilars to PAFSC First Committee on Oct. 29
October 17, 2014
- NIBIO to Begin Drug Seed Optimization Project from FY2015
October 16, 2014
- PAFSC Second Committee to Discuss Janssen’s Combination Tablet for HIV Infection on Oct. 27
October 16, 2014
- 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
- Japan Faces Rocky Road to Ratify Nagoya Protocol on Biodiversity
October 15, 2014
- MHLW Panel OKs Tweaked Requirements for New Development Request Scheme
October 15, 2014
- Council OKs Public-Knowledge Based Application for Solu-Cortef as a Treatment for Bronchial Asthma
October 15, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- National Healthcare Expenditure Hits Record 39 Trillion Yen in FY2012
October 14, 2014
- PFSB Issues Notification on Reporting of Malfunctions of Regenerative Medicine Products
October 14, 2014
- PFSB Issues Notification on Package Inserts of Regenerative Medicine Products
October 14, 2014
- PFSB Announces New Format for ADR Reporting to Be Used Starting in FY2016
October 14, 2014
- MOF Panel to Pitch Reference Pricing for Long-Listed Drugs, Price Cut in FY2015
October 9, 2014
- PMDA Begins Accepting Applications for Regulatory Review Schedule Meetings
October 9, 2014
- Chuikyo to Discuss Handling of Regenerative Medicine Products Under Health Insurance Programs
October 9, 2014
- MHLW to Add Page to Website in FY2016 to Help Hospitals, Pharmacies Select Generic Drug Makers
October 8, 2014
- Minister Calls on Hospitals, Pharmacies to Report Price Settlement Rates within October
October 8, 2014
- Editor’s Pick: Five Healthcare News Headlines for Sept. 22 - Oct. 3
October 6, 2014
- MEXT Redefines Objective of Generic Promotion Subsidy Project to Continue Funding in FY2015
October 6, 2014
- MHLW Panel Agrees that Legal Regulation of Clinical Research Would Be “Difficult”
October 3, 2014
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…